抗體-藥物結(jié)合物（ADC）由理想的單克隆抗體、活性細(xì)胞毒性藥物和合適的連接劑組成。抗體和細(xì)胞毒性藥物之間的適當(dāng)連接物提供特異性橋，從而幫助抗體選擇性地將細(xì)胞毒性藥物遞送至腫瘤細(xì)胞，并在腫瘤部位精確地釋放細(xì)胞毒性藥物
(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide
Boc-NH-PEG6-NH2
3,6,9,12,15,18,21,24,27-Nonaoxanonacosane-1,29-diol
1,1'-((Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(1H-pyrrole-2,5-dione)
(Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(2-ethylhexanoate)
Triethyleneglycolmonobutylether
2-(2-(2-Ethoxyethoxy)ethoxy)ethanol
2-(2-(2-Methoxyethoxy)ethoxy)acetic acid
(Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(3-(3-(tert-butyl)-4-hydroxy-5-methylphenyl)propanoate)
tert-Butyl (23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate
1-(9H-Fluoren-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oic acid
1-(9H-Fluoren-9-yl)-3-oxo-2,7,10,13,16,19-hexaoxa-4-azadocosan-22-oic acid
2-(2-(2-(2-Chloroethoxy)ethoxy)ethoxy)ethanol
N-(2-(2-(2-(3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
2,5,8,11,14,17,20,23-Octaoxahexacosan-26-oic acid
2,5,8,11,14,17,20-Heptaoxadocosan-22-amine
2,5,8,11,14,17-Hexaoxanonadecan-19-amine
tert-Butyl (17-amino-3,6,9,12,15-pentaoxaheptadecyl)carbamate
2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-amine
2,5,8,11,14-Pentaoxahexadecane-16-thiol
2,5,8,11,14,17,20,23-Octaoxapentacosane-25-thiol
2,5,8,11,14-Pentaoxaheptadecan-17-oic acid
2,5,8,11,14,17,20,23,26,29,32-Undecaoxatetratriacontan-34-amine
2,5,8,11,14,17,20-Heptaoxatricosan-23-oic acid
1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid
3,6,9,12,15,18,21,24,27,30-Decaoxadotriacontane-1,32-diamine
(Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate)
2,5,8,11-Tetraoxatetradecan-14-al
